Galapagos NV Company Profile (NASDAQ:GLPG)

About Galapagos NV (NASDAQ:GLPG)

Galapagos NV logoGalapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GLPG
  • CUSIP: N/A
  • Web:
Average Prices:
  • 52 Week Range: $57.16 - $104.12
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -28.24
  • P/E Growth: 0.00
  • Net Margins: -16.29%
  • Return on Equity: -3.42%
  • Return on Assets: -2.46%
  • Current Ratio: 9.83%
  • Quick Ratio: 9.83%
  • Beta: 1.77

Frequently Asked Questions for Galapagos NV (NASDAQ:GLPG)

What is Galapagos NV's stock symbol?

Galapagos NV trades on the NASDAQ under the ticker symbol "GLPG."

When will Galapagos NV make its next earnings announcement?

Galapagos NV is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Galapagos NV.

Where is Galapagos NV's stock going? Where will Galapagos NV's stock price be in 2017?

9 brokers have issued 1 year price objectives for Galapagos NV's shares. Their predictions range from $98.00 to $124.00. On average, they anticipate Galapagos NV's stock price to reach $111.83 in the next year. View Analyst Ratings for Galapagos NV.

What are analysts saying about Galapagos NV stock?

Here are some recent quotes from research analysts about Galapagos NV stock:

  • 1. According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (10/11/2017)
  • 2. Stifel Nicolaus analysts commented, "Aurinia reported 2Q17 financial results in an after market close press release." (8/11/2017)
  • 3. BTIG Research analysts commented, "Supports Thesis for Minimal Function CF Patients Yesterday, Vertex (VRTX, Not Rated) provided top-line results of the first triplet combination studies for Cystic Fibrosis patients with minimal function mutations, which represents 1/3 of the total patient population. Importantly, the triplet combinations also demonstrated improvements with the F508del homozygous population that exceed the clinical benefit of Orkambi. Overall, this first data for triplet therapies provides positive support for the use of two CFTR correctors within one daily regimen. The results from VRTX’s studies are positive for GLPG’s efforts conceptually, but given GLPG’s limited dataset to date, we continue to think that efforts within CF are a ‘show-me’ story. We maintain our Buy rating and $98 PT.   X-440 and VX-152 Triplet Combinations set a new hurdle rate for clinical efficacy: Although the timespans were relatively short, with 29 days studied with VX-440 and 15 days with VX-152, the +9.5% and +7.3% respective improvements of ppFEV1 are impressive within the F508del homozygous population given the study design had a 4 week run-in period with tezacaftor and ivacaftor. Furthermore, the statistically significant improvements in ppFEV1 in both VX-440 and VX-152 studies within the F508del/Min patient population is unprecedented, underscored by the previous failure of the tezacaftor + ivacaftor combination study." (7/20/2017)
  • 4. Cowen and Company analysts commented, "GLPG provided a broad pipeline update at an R&D day." (6/21/2017)
  • 5. Instinet analysts commented, "We are initiating coverage on Galapagos (GLPG) with a buy rating and $87 target price. We believe the company's rapidly advancing cystic fibrosis (CF) pipeline, partnered with AbbVie, will drive shares higher in the next 12 months. We also anticipate an increasing focus on filgotinib's opportunity in Crohn's disease, and ulcerative colitis (UC) in Phase 3 trials, may lead to upside in shares over the next 12-months. In our view, the current valuation is predominantly supported primarily by the blockbuster opportunity for the company's lead oral JAK1 inhibitor, filgotinib (partnered with Gilead), for the treatment of rheumatoid arthritis." (3/1/2017)

Are investors shorting Galapagos NV?

Galapagos NV saw a drop in short interest during the month of September. As of September 15th, there was short interest totalling 403,300 shares, a drop of 27.4% from the August 31st total of 555,345 shares. Based on an average trading volume of 105,234 shares, the short-interest ratio is currently 3.8 days.

Who are some of Galapagos NV's key competitors?

Who are Galapagos NV's key executives?

Galapagos NV's management team includes the folowing people:

  • Onno van de Stolpe, Chief Executive Officer, Executive Director
  • Bart Filius, Chief Financial Officer
  • Andre Hoekema, Senior Vice President - Corporate Development
  • Piet Wigerinck, Chief Scientific Officer
  • Rajesh Parekh, Non-Executive Chairman of the Board
  • Harrold van Barlingen, Non-Executive Director
  • Katrine Bosley, Independent Non-Executive Director
  • Werner Cautreels, Non-Executive Independent Director
  • Christine Mummery, Non-Executive Independent Director

When did Galapagos NV IPO?

(GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Who owns Galapagos NV stock?

Galapagos NV's stock is owned by a number of of institutional and retail investors. Top institutional investors include Eqis Capital Management Inc. (0.00%). View Institutional Ownership Trends for Galapagos NV.

Who bought Galapagos NV stock? Who is buying Galapagos NV stock?

Galapagos NV's stock was bought by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for Galapagos NV.

How do I buy Galapagos NV stock?

Shares of Galapagos NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galapagos NV's stock price today?

One share of Galapagos NV stock can currently be purchased for approximately $101.66.

MarketBeat Community Rating for Galapagos NV (NASDAQ GLPG)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  274
MarketBeat's community ratings are surveys of what our community members think about Galapagos NV and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Galapagos NV (NASDAQ:GLPG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $111.83 (10.01% upside)
Consensus Price Target History for Galapagos NV (NASDAQ:GLPG)
Price Target History for Galapagos NV (NASDAQ:GLPG)
Analysts' Ratings History for Galapagos NV (NASDAQ:GLPG)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Morgan StanleyReiterated RatingOverweight$92.00 -> $123.00N/AView Rating Details
9/15/2017Stifel NicolausBoost Price TargetBuy -> Buy$101.00 -> $120.00LowView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform$98.00MediumView Rating Details
8/11/2017NomuraBoost Price TargetBuy$108.00 -> $124.00LowView Rating Details
8/10/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
7/26/2017BTIG ResearchReiterated RatingBuy$98.00MediumView Rating Details
7/7/2017Janney Montgomery ScottUpgradeSell -> NeutralLowView Rating Details
6/22/2017InstinetReiterated RatingBuy$121.00 -> $108.00LowView Rating Details
10/18/2016Goldman Sachs Group, Inc. (The)UpgradeNeutral -> BuyN/AView Rating Details
6/17/2016Credit Suisse GroupReiterated RatingHold$48.00N/AView Rating Details
12/17/2015Bryan, Garnier & CoBoost Price TargetBuy$52.00 -> $64.00N/AView Rating Details
12/8/2015KBC SecuritiesUpgradeBuyN/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Galapagos NV (NASDAQ:GLPG)
Earnings by Quarter for Galapagos NV (NASDAQ:GLPG)
Earnings History by Quarter for Galapagos NV (NASDAQ GLPG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2015Q3($0.80)$11.46 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Galapagos NV (NASDAQ:GLPG)
Current Year EPS Consensus Estimate: $-2.77 EPS
Next Year EPS Consensus Estimate: $-3.60 EPS


Dividend History for Galapagos NV (NASDAQ:GLPG)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Galapagos NV (NASDAQ:GLPG)
No insider trades for this company have been tracked by


Headline Trends for Galapagos NV (NASDAQ:GLPG)
Latest Headlines for Galapagos NV (NASDAQ:GLPG)
DateHeadline logoGalapagos NV (GLPG) Upgraded to Hold by Zacks Investment Research - October 11 at 10:26 PM logoETFs with exposure to Galapagos NV : October 5, 2017 - October 10 at 3:18 PM logoGalapagos NV (GLPG) Receives Consensus Rating of "Buy" from Brokerages - October 7 at 6:50 PM logoGalapagos NV (GLPG) Stock Rating Reaffirmed by Morgan Stanley - October 7 at 12:22 PM logoETFs with exposure to Galapagos NV : October 5, 2017 - October 5 at 7:05 PM logoGalapagos Pops After Eczema Drug Shows Promise Vs. Regeneron - October 2 at 2:00 PM logoGalapagos NV (GLPG) Sees Large Decline in Short Interest - September 30 at 2:34 AM logoForm 6-K GALAPAGOS NV For: Sep 27 - September 27 at 10:15 PM logoGalapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients - September 27 at 3:04 AM logoETFs with exposure to Galapagos NV : September 19, 2017 - September 19 at 7:06 PM logoGalapagos NV :GLPG-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 - September 18 at 6:37 PM logoGalapagos NV (GLPG) PT Raised to $120 at Stifel on Positive KOL Feedback on GLPG1690 for IPF - - September 16 at 6:25 PM logoGalapagos NV (GLPG) Price Target Raised to $120.00 - September 15 at 7:28 AM logoGalapagos NV (GLPG) Coverage Initiated by Analysts at Royal Bank Of Canada - September 14 at 9:50 PM logoGalapagos NV (GLPG) Given Consensus Recommendation of "Buy" by Analysts - September 12 at 6:26 PM logoGalapagos NV (GLPG) Receives Average Recommendation of "Buy" from Brokerages - August 18 at 6:32 PM logo3 Things In Biotech You Should Learn Today: August 14, 2017 - Seeking Alpha - August 14 at 7:27 PM logoGalapagos NV (NASDAQ:GLPG) Upgraded at Stifel Nicolaus - August 13 at 7:14 PM logoNomura Boosts Galapagos NV (GLPG) Price Target to $124.00 - August 12 at 10:56 PM logoStifel Upgrades Galapagos NV (GLPG) to Buy - - August 12 at 12:37 AM logoMorgan Stanley Expects Galapagos Shares To Rise 10% - August 11 at 12:12 AM logoGalapagos NV (GLPG) Says GLPG1690 Halts Disease Progression in IPF Patients in FLORA Phase 2a Trial - August 11 at 12:12 AM logoMorgan Stanley Reiterates "Overweight" Rating for Galapagos NV (NASDAQ:GLPG) - August 10 at 11:34 PM logoCowen and Company Reaffirms "Buy" Rating for Galapagos NV (NASDAQ:GLPG) - August 10 at 4:32 PM logoGLPG's FLORA Blooms, DVAX, ESPR Price Offering, SGMO Abuzz, HRTX On Track - Nasdaq - August 10 at 5:24 AM logoGLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial - August 9 at 7:16 PM logoIs a Surprise Coming for Galapagos (GLPG) This Earnings Season? - August 3 at 9:12 PM logoGalapagos NV (NASDAQ:GLPG) Expected to Post FY2017 Earnings of ($2.23) Per Share - August 2 at 10:38 AM logo$27.35 Million in Sales Expected for Galapagos NV (NASDAQ:GLPG) This Quarter - August 1 at 9:14 AM logoSolid financials support R&D progress - GlobeNewswire (press release) - July 28 at 5:44 AM logoSolid financials support R&D progress - Nasdaq - July 27 at 7:37 PM logoServier licenses GLPG1972 in osteoarthritis from Galapagos - July 27 at 7:37 PM logoSolid financials support R&D progress - July 27 at 7:37 PM logoGalapagos NV (GLPG) Earns Buy Rating from BTIG Research - July 26 at 4:31 PM logoGalapagos NV (NASDAQ:GLPG) Receives Average Recommendation of "Buy" from Analysts - July 24 at 6:52 PM logoGalapagos (GLPG) Looks Good: Stock Adds 6.2% in Session - Nasdaq - July 22 at 12:32 AM logoGalapagos NV (GLPG) Receives Buy Rating from BTIG Research - July 20 at 8:43 AM logoVertex Pharma shares hit life high as cystic fibrosis data wows - July 19 at 7:45 PM logoVertex Hits Record High On Results Of Cystic Fibrosis Trial - July 19 at 7:45 PM logoEnanta Pharmaceuticals (ENTA) and Galapagos NV (GLPG) Head-To-Head Review - July 16 at 8:08 AM logoTiGenix: This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come - July 13 at 12:47 AM logoGalapagos NV (NASDAQ:GLPG) Upgraded to "Neutral" by Janney Montgomery Scott - July 7 at 11:46 PM logo$26.50 Million in Sales Expected for Galapagos NV (GLPG) This Quarter - July 7 at 11:36 AM logoGalapagos NV (NASDAQ:GLPG) Expected to Post Earnings of -$0.68 Per Share - July 5 at 10:18 PM logoGalapagos NV: New Phase 2 study with filgotinib in non-infectious uveitis - July 5 at 7:43 PM logoGalapagos NV (GLPG) Announces New Phase II Study With Filgotinib In Non-infectious Uveitis - - July 5 at 7:40 AM logoGalapagos NV (GLPG) PT Lowered to $108 at Instinet Following the company's R&D Day - - June 22 at 9:27 AM logoGalapagos updates investors in R&D programs - June 21 at 4:13 AM logoGalapagos NV (GLPG) Reports Increase in Share Capital Through Warrant Exercises - June 21 at 4:13 AM logoGalapagos NV (GLPG) Reports Increase in Share Capital Through Warrant Exercises - - June 20 at 6:13 PM



Galapagos NV (GLPG) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.